source
- Kailera and Hengrui’s GLP-1/GIP candidate ribupatide cuts weight up to 20% and restores menstrual cycles in Phase 2 PMOS trialKailera Therapeutics and Hengrui Pharma reported positive results from a Phase 2 study of their weekly injectable GLP-1/GIP dual agonist, ribupatide, in women with polyendocrine metabolic ovarian s…
- NIH awards all grant money but delays and opaque decisions hinder researchers, cuts health disparity fundingThe National Institutes of Health announced that it has allocated the full amount of its grant budget for fiscal year 2026, but the timing and transparency of award decisions have been problematic…STAT · 19d agoRegulatoryNegative